Zenbexus (iberdomide)
Bristol Myers Squibb (BMY)
ApprovedAug 13, 2026
Marketer take
An oral CELMoD used with daratumumab-based therapy after one prior line including a PI and IMiD, so it targets community oncologists' early-relapse sequencing decisions rather than the late-line centers where CAR-T competes.
- Sponsor company
- Bristol Myers Squibb (BMY)
- Indication
- To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Therapeutic area
- Oncology, Hematology
- Event
- FDA approval
- Date
- Aug 13, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?